Biomea Fusion is a clinical-stage biopharmaceutical company focused on the discovery and development of covalent small molecules to treat patients with genetically defined cancers and metabolic diseases. Co. has built its proprietary FUSION System discovery platform to develop a pipeline of covalent small molecule product candidates. Co.'s product candidate, BMF-219, is designed to be an orally bioavailable, selective irreversible covalent inhibitor of menin, a scaffold protein that functions in histone modification and epigenetic gene regulation to impact multiple cellular processes including cell cycle control, apoptosis, and DNA damage repair. The BMEA average annual return since 2021 is shown above.
The Average Annual Return on the BMEA average annual return since 2021 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether BMEA average annual return since 2021 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the BMEA average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|